IL17A and myeloid sarcoma: Remarkably, the receptors for IL-17 and IL-22 are absent in CNS samples from healthy human subjects, but they are strongly expressed on CNS endothelial cells within MS lesions, suggesting that the human BBB is highly responsive to the detrimental effect of these two cytokines (Kebir et al., 2007).